Barclays Analysts Give Merck KGaA (FRA:MRK) a €85.00 Price Target

Share on StockTwits

Barclays set a €85.00 ($98.84) price target on Merck KGaA (FRA:MRK) in a research report released on Tuesday morning, Borsen Zeitung reports. The firm currently has a sell rating on the healthcare company’s stock.

A number of other research firms have also issued reports on MRK. Bank of America set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Friday, September 13th. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday. HSBC set a €96.00 ($111.63) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Thursday, August 15th. Morgan Stanley set a €96.00 ($111.63) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Tuesday, September 10th. Finally, DZ Bank reiterated a buy rating on shares of Merck KGaA in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of €101.78 ($118.35).

Shares of MRK traded down €3.60 ($4.19) during mid-day trading on Tuesday, reaching €106.15 ($123.43). 1,028,425 shares of the stock traded hands. The stock has a fifty day simple moving average of €105.33 and a 200 day simple moving average of €96.85. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: Dead Cat Bounce

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.